ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster
August 07, 2018Ironwood Pharmaceuticals has decided to walk away from its 2016 deal to license AstraZeneca’s billion-dollar gout treatment lesinurad in the U.S., following poor market performance of the drug, as Ironwood continues its march toward splitting into two sep
Pharma Sources Insight January 2025
